Literature DB >> 19369901

Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.

Bianca Costa Soares de Sá1, Melissa Lissae Fugimori, Karina de Cássia Braga Ribeiro, João Pedreira Duprat Neto, Rogério Izar Neves, Gilles Landman.   

Abstract

Cutaneous melanoma is one of the leading causes of cancer-related death. Malignant transformation of epidermal melanocytes is a multifactorial process involving cell cycle and death control pathways. The purpose of this study was to analyze the immunohistochemical expression of cell-cycle-related and apoptosis-related proteins in cutaneous superficial spreading melanomas using the tissue microarray technique to further understand tumor development. A total of 20 samples of in-situ melanomas and 44 melanomas <or=1.0 mm were analyzed in conventional sections whereas 72 melanomas greater than 1.0 mm and 29 metastases were evaluated by tissue microarray. The sections were stained for the following proteins: p16INK4 (p16), cyclin D1, cyclin-dependent kinase 4 (Cdk4), retinoblastoma protein, tumor suppressor protein p53, and p21 cell cycle regulator (p21) using a streptavidine-biotin-peroxidase technique for immunohistochemistry. Thick melanomas (>1.0 mm) and metastases lost p16 expression in 100% of the cases and in-situ and thin melanomas (<or=1.0 mm) had low rate of p16 expression (7.9%). When comparing thin versus thick melanomas, thin melanomas showed higher expression of cyclin D1 and cytoplasmatic Cdk4, and thick melanomas had increased expression of nuclear Cdk4, tumor suppressor protein p53, and p21. Primary tumors, when compared with metastases, had higher cytoplasmatic Cdk4 expression. None of the studied proteins influenced overall or disease-free survival. Our results suggest that loss of p16 expression was a constant feature in primary and metastatic melanomas. Cyclin D1 expression seems to be related to initial phases of melanoma development. An increase in p21 expression could represent a cell cycle control in proliferating cells with reduced p16 and/or increased nuclear Cdk4 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369901     DOI: 10.1097/CMR.0b013e32831993f3

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  9 in total

1.  Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.

Authors:  Gergo Kiszner; Barnabas Wichmann; Istvan B Nemeth; Erika Varga; Nora Meggyeshazi; Ivett Teleki; Peter Balla; Mate E Maros; Karoly Penksza; Tibor Krenacs
Journal:  Virchows Arch       Date:  2014-03-30       Impact factor: 4.064

2.  Correlation of cell cycle regulatory proteins (p53 and p16(ink)⁴(a)) and bcl-2 oncoprotein with mitotic index and thickness of primary cutaneous malignant melanoma.

Authors:  Miloš Kostov; Zaklina Mijović; Dragan Mihailović; Snežana Cerović; Miroslav Stojanović; Marija Jelić
Journal:  Bosn J Basic Med Sci       Date:  2010-11       Impact factor: 3.363

3.  Cyclin D1 and D3 expression in melanocytic skin lesions.

Authors:  Ana Alekseenko; Anna Wojas-Pelc; Grzegorz J Lis; Alicja Furgał-Borzych; Grzegorz Surówka; Jan A Litwin
Journal:  Arch Dermatol Res       Date:  2010-05-23       Impact factor: 3.017

4.  Zebrafish have a competent p53-dependent nucleotide excision repair pathway to resolve ultraviolet B-induced DNA damage in the skin.

Authors:  Zhiqiang Zeng; Jennifer Richardson; Daniel Verduzco; David L Mitchell; E Elizabeth Patton
Journal:  Zebrafish       Date:  2009-12       Impact factor: 1.985

5.  Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma.

Authors:  Valcinir Bedin; Randall L Adam; Bianca Cs de Sá; Gilles Landman; Konradin Metze
Journal:  BMC Cancer       Date:  2010-06-05       Impact factor: 4.430

Review 6.  Epigenetics in the Diagnosis and Therapy of Malignant Melanoma.

Authors:  Simeon Santourlidis; Wolfgang A Schulz; Marcos J Araúzo-Bravo; Daniela Gerovska; Pauline Ott; Marcelo L Bendhack; Mohamed Hassan; Lars Erichsen
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

7.  High prevalence of p16 staining in malignant tumors.

Authors:  Noémi De Wispelaere; Sebastian Dwertmann Rico; Marcus Bauer; Andreas M Luebke; Martina Kluth; Franziska Büscheck; Claudia Hube-Magg; Doris Höflmayer; Natalia Gorbokon; Sören Weidemann; Katharina Möller; Christoph Fraune; Christian Bernreuther; Ronald Simon; Christian Kähler; Anne Menz; Andrea Hinsch; Frank Jacobsen; Patrick Lebok; Till Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Eike Burandt; Rainer Krech; David Dum; Till Krech; Andreas Marx; Sarah Minner
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

8.  The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate variant antigen binding.

Authors:  Magdalena Sawicka; Jeffrey Pawlikowski; Stephen Wilson; Dudley Ferdinando; Hong Wu; Peter David Adams; David Andrew Gunn; William Parish
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

9.  p16 Expression Is Lost in Severely Atypical Cellular Blue Nevi and Melanoma Compared to Conventional, Mildly, and Moderately Atypical Cellular Blue Nevi.

Authors:  Laura M Chang; David S Cassarino
Journal:  ISRN Dermatol       Date:  2014-01-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.